August 25th, 22
Social Survey Research Information Co., Ltd.
Social Survey Research Information Co., Ltd.
NEWS
Analysis by scale of hospitals and cities by the top 10 companies in China in terms of sales rep activities (6 foreign-funded and 4 domestic-funded).
Sales rep activities commonly focus on Tier 3 hospitals (large-scale hospitals).
The top 3 foreign-funded companies have high coverage in cities of each scale, and AZ also stands out for its coverage of smaller cities.
Other foreign-funded companies tend to focus on large cities, while Chinese domestic-funded companies tend to focus on regional cities.
Eisai is the top Japanese-affiliated company in terms of visiting coverage, and the second-ranked Takeda similarly places importance on activities in large cities.
Social Survey Research Information Co., Ltd. and M3 Inc. conducted an analysis of the differences in the activities of pharmaceutical company MRs by hospital scale and city scale using data from the Chinese edition of PatientsMap 2022 based on a physician survey.
This survey was conducted from the end of 2021 to the beginning of March 2022, and the analysis was conducted based on the understanding that the survey results were obtained under near-normal conditions in which the spread of COVID-19 was under control in China.
First, with regard to the top 10 pharmaceutical companies in terms of the percentage of physicians visited by their sales reps in the past month, we compared the percentages of sales rep visits by hospital scale (Table 1).
All of the companies had a high percentage of sales rep visits to Tier 3 hospitals, which are the large-scale hospitals in China, and the same trend was observed for Eisai and Takeda, the top-ranking Japanese companies.
Next, we compared the percentages of sales rep visits to the Tier 3 hospitals which tended to have a high percentage of sales rep visits by city scale (Table 2). The analysis was conducted by dividing the cities into three classes by city scale: Tier 1, Tier 1.5/2, and Tier 3 or lower. Note that the smaller the number in the class, the larger the city scale.
Among foreign-funded pharmaceutical companies, AstraZeneca, Pfizer, and Bayer, the top three in terms of the percentage of sales rep visits, showed a high percentage of sales rep visits in all city classes, with AZ in particular having a high percentage of visits even in the smaller Tier 3 cities. For foreign-funded pharmaceutical companies other than the top three in terms of the percentage of sales rep visits, the larger the city, the higher the percentage of sales rep visits. Conversely, for the Chinese domestic-funded pharmaceutical companies, the smaller the city, the higher the percentage of sales rep visits.
For Eisai and Takeda, the top two Japanese-affiliated companies, as the percentage of sales rep visits was higher for larger cities, a trend similar to the foreign-funded pharmaceutical companies except for the top three in terms of the percentage of sales rep visits was observed.
PatientsMap is a large-scale database that enlists the cooperation of physicians and examines physician coverages and patient numbers for approximately 400 diseases, unmet medical needs (hope for new drugs), and the activities of real (in-person) sales reps and e-detailing activities of pharmaceutical companies.
This is the third survey conducted in China targeted for member physicians on a portal site for medical professionals operated by Medlive.cn, an M3 Group company, with 11,000 physicians responding online.
(Table 1) Comparison of the percentage of physicians who reported receiving sales rep visits between Tier 3 and non-Tier 3 hospitals
| (Reference) Overall n=11,106 | Tier 3 hospitals n=8,092 | Other than Tier 3 hospitals n=2,677 | ||
|---|---|---|---|---|
| 1.AstraZeneca | 27.6% | 28.1% | 27.3% | |
| 2.Pfizer | 22.9% | 24.4% | 19.5% | |
| 3.Bayer | 19.8% | 20.3% | 18.9% | |
| 4.Chia Tai Tianqing | 18.7% | 21.2% | 12.4% | |
| 5.Qilu | 17.4% | 19.1% | 13.6% | |
| 6.Novartis | 16.9% | 18.8% | 12.1% | |
| 7.Yangtze River | 16.9% | 17.9% | 14.9% | |
| 8.MSD | 16.5% | 18.3% | 11.9% | |
| 9.Jiangsu Hengrui | 14.3% | 16.9% | 7.8% | |
| 10.Sanofi | 13.2% | 13.6% | 12.9% | |
| 25.Eisai | 6.7% | 7.7% | 4.0% | |
| 27.Takeda Pharmaceutical | 6.0% | 7.1% | 3.0% |
(Table 2) Comparison of the percentage of physicians who reported receiving sales rep visits in Tier 3 hospitals by city classification
| Tier 3 hospitals | |||
|---|---|---|---|
| Tier 1 cities n=1,170 | Tier 1.5/2 cities n=3,764 | Tier 3 or lower cities n=3,158 | |
| AstraZeneca | 25.4% | 27.2% | 30.2% |
| Pfizer | 24.2% | 24.7% | 24.2% |
| Bayer | 21.7% | 19.9% | 20.2% |
| Chia Tai Tianqing | 16.4% | 22.1% | 21.9% |
| Qilu | 16.3% | 18.3% | 21.2% |
| Novartis | 20.3% | 19.8% | 17.1% |
| Yangtze River | 14.3% | 17.5% | 19.6% |
| MSD | 20.3% | 20.1% | 15.3% |
| Jiangsu Hengrui | 13.5% | 18.3% | 16.4% |
| Sanofi | 13.7% | 13.5% | 13.6% |
| Eisai | 9.7% | 8.1% | 6.6% |
| Takeda Pharmaceutical | 8.9% | 8.3% | 5.1% |
Data souce:PatientsMap2022CN
*The overall population of the analysis was physicians working at general hospitals, specialized hospitals (excluding Chinese medicine hospitals), and Chinese medicine hospitals/Chinese traditional and Western medicine hospitals.
*Chinese domestic pharmaceutical companies are shown in bold.
*In Table 1, analysis was conducted for the top 10 companies with the highest percentages on the whole and the top two Japanese-affiliated companies.
*When compared horizontally, cells with a difference of at least 3 points from the cell with the smallest value are shaded in yellow, and cells with a difference of at least 5 points are shaded in green.
(Reference) City Classification by Region
Tier 1 cities
| Beijing | Shanghai | Guangzhou, Guangdong Province | Shenzhen, Guangdong Province |
Tier 1.5 cities
| Chongqing | Tianjin | Dongguan, Guangdong Province | Zhenzhou, Henan Province | Wuhan, Hubei Province |
| Changsha, Hunan Province | Nanjing, Jiangsu Province | Suzhou, Jiangsu Province | Dalian, Liaoning Province | Shenyang, Liaoning Province |
| Xi'an, Shaanxi Province | Qingdao, Shandong Province | Chengdu, Sichuan Province | Hangzhou, Zhejiang Province | Ningbo, Zhejiang Province |
Tier 2 cities
| Hefei, Anhui Province | Fuzhou, Fujian Province | Quanzhou, Fujian Province | Xiamen, Fujian Province | Lanzhou, Gansu Province |
| Foshan, Guangdong Province | Huizhou, Guangdong Province | Zhongshan, Guangdong Province | Zhuhai, Guangdong Province | Nanning, Guangxi Zhuang Autonomous Region |
| Guiyang, Guizhou Province | Haikou, Hainan Province | Shijiazhuang, Hebei Province | Harbin, Heilongjiang Province | Changzhou, Jiangsu Province |
| Nantong, Jiangsu Province | Wuxi, Jiangsu Province | Xuzhou, Jiangsu Province | Yangzhou, Jiangsu Province | Nanchang, Jiangxi Province |
| Changchun, Jilin Province | Jinan, Shandong Province | Yantai, Shandong Province | Taiyuan, Shanxi Province | Urumqi, Xinjiang Uygur Autonomous Region |
| Kunming, Yunnan Province | Jiaxin, Zhejiang Province | Jinhua, Zhejiang Province | Shaoxing, Zhejiang Province | Taizhou, Zhejiang Province |
| Wenzhou, Zhejiang Province |
Outline of the "Chinese Edition of PatientsMap 2022 (PatientsMap 2022CN)" study
The survey was conducted among member physicians on a portal site for medical professionals operated by Medlive.cn, an M3 Group company:| Condition coverage | : | 402 conditions |
|---|---|---|
| Target respondents | : | Medlive.cn-registered physicians (excluding associate physicians) Physicians in higher positions of all specialties at hospitals and clinics (chief physicians, deputy chief physicians, attending physicians) |
| Inclusion criteria | : | Physicians of all specialties at hospitals and clinics |
| Method | : | Online survey |
| Number of cooperating physicians | : | 11,106 |
| Fieldwork period | : | December 27, 2021 to March 4, 2022 |
| Survey item: | : | Number of patients seen (in the past month) Number of patients who were prescribed drugs (in the past month) Conditions for which new drugs are desired Companies from which the respondents received a sales rep visit (in the past month) Companies from which the respondents received information by means other than face-to-face (in the past month) Companies from which the respondents received information from other than sales reps by means other than face-to-face (in the past month) Companies the respondents trust Primary specialty Facility where the respondents primarily work (area, type of facility, facility class, number of beds) Post Age |
In Japan, this service will be jointly provided by Social Survey Research Information Co., Ltd. and M3, Inc.
Contact Information
| Social Survey Research Information Co., Ltd. | |
|---|---|
| patientsmap@ssri.com | |
| Social Survey Research Information Co., Ltd. | |
|---|---|
| Established | April 1982 |
| Capital | 27 million JPY |
| President & CEO | Takashi Makita |
| Number of employees | 137 |
| Location | Head Office NMF Shinjuku East Bldg. 2F, 3F 10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN |
| Osaka office Daimei Bldg. 4F, 4-6-3 Hirano-cho, Chuo-ku, Osaka 541-0046 JAPAN | |
| Affiliate companies | PD Research Co., Ltd. MDB Co. SSRI China Co., Ltd. (overseas subsidiary) SSRI Asia Pacific Co., Ltd. (overseas subsidiary) HIMA Research (overseas affiliate) |
| URL | https://www.ssri.com/ |
| M3, Inc. | |
|---|---|
| Established | September 2000 |
| Capital | 29.129 billion JPY (as of March 31, 2022) |
| Representative Director | Itaru Tanimura |
| Number of employees, consolidated | 89,384 (as of March 31, 2022) |
| Location | Akasaka Intercity 10F 1-11-44 Akasaka, Minato-ku, Tokyo |
| URL | https://corporate.m3.com/ |